Cargando…

Impact of Duration of N-Acetylcysteine in Non-Acetaminophen–Induced Acute Liver Failure

OBJECTIVES: Studies of the use of IV N-acetylcysteine in the management of non-acetaminophen-induced acute liver failure have evaluated various dosing regimens. The only randomized trial studying this application described a 72-hour regimen. However, observational studies have reported extended dura...

Descripción completa

Detalles Bibliográficos
Autores principales: Bass, Stephanie N., Lumpkin, Mollie, Mireles-Cabodevila, Eduardo, Lindenmeyer, Christina C., Dolan, Bridget, Pickett, Caleigh, Kapoor, Aanchal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8133178/
https://www.ncbi.nlm.nih.gov/pubmed/34036270
http://dx.doi.org/10.1097/CCE.0000000000000411
_version_ 1783695030738747392
author Bass, Stephanie N.
Lumpkin, Mollie
Mireles-Cabodevila, Eduardo
Lindenmeyer, Christina C.
Dolan, Bridget
Pickett, Caleigh
Kapoor, Aanchal
author_facet Bass, Stephanie N.
Lumpkin, Mollie
Mireles-Cabodevila, Eduardo
Lindenmeyer, Christina C.
Dolan, Bridget
Pickett, Caleigh
Kapoor, Aanchal
author_sort Bass, Stephanie N.
collection PubMed
description OBJECTIVES: Studies of the use of IV N-acetylcysteine in the management of non-acetaminophen-induced acute liver failure have evaluated various dosing regimens. The only randomized trial studying this application described a 72-hour regimen. However, observational studies have reported extended duration until normalization of international normalized ratio. This study seeks to compare differences in patient outcomes based on IV N-acetylcysteine duration. DESIGN: Retrospective cohort study. SETTING: Medical ICU at a large quaternary care academic medical institution and liver transplant center. PATIENTS: Adult patients admitted to the medical ICU who received IV N-acetylcysteine for the treatment of non-acetaminophen-induced acute liver failure. INTERVENTIONS: Patients were divided into cohorts based on duration; standard duration of IV N-acetylcysteine was considered 72 hours, whereas extended duration was defined as continuation beyond 72 hours. MEASUREMENTS AND MAIN RESULTS: The primary outcome was time to normalization of international normalized ratio to less than 1.3 or less than 1.5; secondary outcomes included all-cause mortality and transplant-free survival at 3 weeks. In total, 53 patients were included: 40 in the standard duration cohort and 13 in the extended duration. There were no major differences in baseline characteristics. There was no significant difference in time to international normalized ratio normalization between cohorts. Transplant-free survival was higher with extended duration (76.9% extended vs 41.4% standard; p = 0.03). All-cause mortality at 3 weeks was numerically lower in the extended duration group (0% extended vs 24.1% standard; p = 0.08). CONCLUSIONS: Patients with non-acetaminophen-induced acute liver failure who received extended duration N-acetylcysteine were found to have significantly higher transplant-free survival than patients who received standard duration, although there was no significant difference in time to normalization of international normalized ratio or overall survival. Prospective, randomized, multicenter study is warranted to identify subpopulations of patients with non-acetaminophen-induced acute liver failure who could benefit from extended treatment duration as a bridge to transplant or spontaneous recovery.
format Online
Article
Text
id pubmed-8133178
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-81331782021-05-24 Impact of Duration of N-Acetylcysteine in Non-Acetaminophen–Induced Acute Liver Failure Bass, Stephanie N. Lumpkin, Mollie Mireles-Cabodevila, Eduardo Lindenmeyer, Christina C. Dolan, Bridget Pickett, Caleigh Kapoor, Aanchal Crit Care Explor Observational Study OBJECTIVES: Studies of the use of IV N-acetylcysteine in the management of non-acetaminophen-induced acute liver failure have evaluated various dosing regimens. The only randomized trial studying this application described a 72-hour regimen. However, observational studies have reported extended duration until normalization of international normalized ratio. This study seeks to compare differences in patient outcomes based on IV N-acetylcysteine duration. DESIGN: Retrospective cohort study. SETTING: Medical ICU at a large quaternary care academic medical institution and liver transplant center. PATIENTS: Adult patients admitted to the medical ICU who received IV N-acetylcysteine for the treatment of non-acetaminophen-induced acute liver failure. INTERVENTIONS: Patients were divided into cohorts based on duration; standard duration of IV N-acetylcysteine was considered 72 hours, whereas extended duration was defined as continuation beyond 72 hours. MEASUREMENTS AND MAIN RESULTS: The primary outcome was time to normalization of international normalized ratio to less than 1.3 or less than 1.5; secondary outcomes included all-cause mortality and transplant-free survival at 3 weeks. In total, 53 patients were included: 40 in the standard duration cohort and 13 in the extended duration. There were no major differences in baseline characteristics. There was no significant difference in time to international normalized ratio normalization between cohorts. Transplant-free survival was higher with extended duration (76.9% extended vs 41.4% standard; p = 0.03). All-cause mortality at 3 weeks was numerically lower in the extended duration group (0% extended vs 24.1% standard; p = 0.08). CONCLUSIONS: Patients with non-acetaminophen-induced acute liver failure who received extended duration N-acetylcysteine were found to have significantly higher transplant-free survival than patients who received standard duration, although there was no significant difference in time to normalization of international normalized ratio or overall survival. Prospective, randomized, multicenter study is warranted to identify subpopulations of patients with non-acetaminophen-induced acute liver failure who could benefit from extended treatment duration as a bridge to transplant or spontaneous recovery. Lippincott Williams & Wilkins 2021-05-14 /pmc/articles/PMC8133178/ /pubmed/34036270 http://dx.doi.org/10.1097/CCE.0000000000000411 Text en Copyright © 2021 The Authors. Published by Wolters Kluwer Health, Inc. on behalf of the Society of Critical Care Medicine. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
spellingShingle Observational Study
Bass, Stephanie N.
Lumpkin, Mollie
Mireles-Cabodevila, Eduardo
Lindenmeyer, Christina C.
Dolan, Bridget
Pickett, Caleigh
Kapoor, Aanchal
Impact of Duration of N-Acetylcysteine in Non-Acetaminophen–Induced Acute Liver Failure
title Impact of Duration of N-Acetylcysteine in Non-Acetaminophen–Induced Acute Liver Failure
title_full Impact of Duration of N-Acetylcysteine in Non-Acetaminophen–Induced Acute Liver Failure
title_fullStr Impact of Duration of N-Acetylcysteine in Non-Acetaminophen–Induced Acute Liver Failure
title_full_unstemmed Impact of Duration of N-Acetylcysteine in Non-Acetaminophen–Induced Acute Liver Failure
title_short Impact of Duration of N-Acetylcysteine in Non-Acetaminophen–Induced Acute Liver Failure
title_sort impact of duration of n-acetylcysteine in non-acetaminophen–induced acute liver failure
topic Observational Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8133178/
https://www.ncbi.nlm.nih.gov/pubmed/34036270
http://dx.doi.org/10.1097/CCE.0000000000000411
work_keys_str_mv AT bassstephanien impactofdurationofnacetylcysteineinnonacetaminopheninducedacuteliverfailure
AT lumpkinmollie impactofdurationofnacetylcysteineinnonacetaminopheninducedacuteliverfailure
AT mirelescabodevilaeduardo impactofdurationofnacetylcysteineinnonacetaminopheninducedacuteliverfailure
AT lindenmeyerchristinac impactofdurationofnacetylcysteineinnonacetaminopheninducedacuteliverfailure
AT dolanbridget impactofdurationofnacetylcysteineinnonacetaminopheninducedacuteliverfailure
AT pickettcaleigh impactofdurationofnacetylcysteineinnonacetaminopheninducedacuteliverfailure
AT kapooraanchal impactofdurationofnacetylcysteineinnonacetaminopheninducedacuteliverfailure